

DiaMedica

13:18 01 Dec 2011

DiaMedica's DM-204 Type 2 diabetes treatment shows promising results

DiaMedica (CVE:DMA) Thursday announced the presentation of new Type 2 diabetes data from studies of its DM-204 monoclonal antibody at the Windhover Therapeutic Area Partnership Conference in Boston.

Shares were up 10 percent to \$1.22 Thursday afternoon.

In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model. Type 2 diabetes is a metabolic disorder that is characterized by high blood glucose levels, due to insulin resistance or insulin deficiency, usually brought on by other conditions such as obesity.

The disease is often initially managed by increasing exercise and dietary modification, but if the condition progresses, insulin injections or oral medication may be necessary.

Treatment with DM-204 resulted in statistically significant lower mean differences compared to untreated animals after 21 days for the following parameters: 2.6 percent lower HbA1c levels at day 21; 70 percent lower difference in fasting blood glucose levels; 25 mm/Hg lower difference in systolic blood pressure levels and less than 20 percent improvement in total cholesterol levels.

Managing each of these parameters is important in the treatment of patients suffering from Type 2 diabetes. An HbA1c test measures a person's average blood sugar levels over a period of three months.

DiaMedica's Scientific Advisory Board member, Dr. John Amatruda, said: "These results are very encouraging and provide a strong foundation with which to move DM-204 forward."

DiaMedica's vice president of research, Dr. Mark Williams, added: "DM-204 has the opportunity to fundamentally change the treatment regimen for Type 2 diabetes patients with hypertension and high cholesterol.

"DM-204 could potentially become the single long-acting treatment by virtue of being a monoclonal antibody therapy. The chronic in vivo model data shows DM-204's ability to prevent disease progression of Type 2 diabetes and increased blood pressure."

Reduction in HbA1c is the critical endpoint measurement in receiving regulatory approval for a Type 2 diabetes medication.

Approximately 70 percent of Type 2 diabetics are prescribed antihypertensive medication to control blood pressure and prevent heart disease and stroke.

The antihypertensive and cholesterol-lowering ability of DM-204 may significantly reduce the need for such medication(s), and furthermore protect Type 2 diabetics from heart disease and stroke complications.

Market Cap: \$0.00

Share Information

Code: DMA
Listing: TSX-V
Sector: Pharma & Biotech
Website: www.diamedica.com

Company Synopsis:

DiaMedica Inc. (DiaMedica) is a biopharmaceutical company that develops therapeutic products designed for Type 1 diabetes, Type 2 diabetes treatment and certain other medically-unmet diseases.

action@proactiveinvestors.com

Administration of DM-204 was also well-tolerated and outperformed marketed Type 2 diabetes drugs sitagliptin (known as Januvia) and exenatide (known as Byetta), the company said.

The full results are to be published and presented in 2012.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.